Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sandoz Group Ltd ( (CH:SDZ) ) has provided an announcement.
Sandoz has launched TYRUKO® (natalizumab-sztn), the first and only FDA-approved biosimilar for multiple sclerosis in the US, marking a significant step in making MS treatment more affordable. This launch is expected to drive growth for Sandoz and strengthen its position in the neurology market, as TYRUKO® is also available in 14 European countries. The drug is part of a broader strategy to lead in the biosimilars market, with Sandoz partnering with Labcorp to provide free testing for anti-JCV antibodies, enhancing patient access and safety.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF74.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz Group Ltd is a global leader in affordable medicines, specializing in biosimilars and generic pharmaceuticals. The company focuses on expanding access to critical and potentially life-changing biologic medicines. With a strong portfolio of marketed biosimilars and ongoing development projects, Sandoz aims to lead in the biosimilars market, particularly in the US and globally in the treatment of multiple sclerosis.
YTD Price Performance: 50.27%
Average Trading Volume: 694,525
Technical Sentiment Signal: Buy
Current Market Cap: CHF24.13B
For a thorough assessment of SDZ stock, go to TipRanks’ Stock Analysis page.